Autologous vs Allogeneic Cell Therapy Regulatory Strategy in 2023: US FDA Expectations Autologous vs Allogeneic Cell Therapy Regulatory Strategy in 2023: US FDA Expectations The field of cell therapy continues to evolve rapidly, with significant implications for regulatory strategy and compliance. Understanding the nuances between autologous and allogeneic cell therapies is essential for professionals engaged in cell therapy regulatory consulting. This article provides a detailed, step-by-step guide to navigating the regulatory requirements set forth by the US FDA, emphasizing critical actions and documentation necessary to develop an effective regulatory strategy in 2023. Step 1: Understanding the Basics of Autologous and…

CMC Comparability Strategy for CAR-T Process Changes in 2023: FDA Reviewer-Ready Package CMC Comparability Strategy for CAR-T Process Changes in 2023: FDA Reviewer-Ready Package Step 1: Understanding CMC Comparability for CAR-T Products In the realm of Advanced Therapy Medicinal Products (ATMPs), particularly in CAR-T cell therapies, establishing a robust Chemistry, Manufacturing, and Controls (CMC) comparability strategy is paramount for regulatory compliance. Comparability assessments are critical when any process change is initiated, ensuring that the therapeutic product’s safety, efficacy, and quality remain consistent. The first step in developing a comparability strategy involves defining what constitutes a manufacturing change. These changes can…

Potency Assay Strategy for Cell Therapy Products in 2023: Validation and Acceptance Criteria Potency Assay Strategy for Cell Therapy Products in 2023: Validation and Acceptance Criteria The development of cell therapy products, particularly in the realm of advanced therapy medicinal products (ATMPs), necessitates rigorous attention to regulatory compliance, particularly concerning potency assays. This comprehensive guide details the essential steps and considerations in developing a potency assay strategy for cell therapy products, focusing on validation and acceptance criteria as mandated by regulatory authorities. Professionals involved in cell therapy regulatory consulting will benefit from the clarity provided herein, which aligns with current…

Global Regulatory Pathway Map for Cell Therapies in 2023: US, EU, UK, Japan Alignment Global Regulatory Pathway Map for Cell Therapies in 2023: US, EU, UK, Japan Alignment The development of cell therapies has advanced rapidly, shaping the landscape of regenerative medicine and oncology treatment. However, navigating the complex regulatory framework governing these Advanced Therapy Medicinal Products (ATMPs) can be daunting for manufacturers and researchers. This guide provides a comprehensive, step-by-step overview of the regulatory pathways for cell therapies in the US, EU, UK, and Japan, with a focus on practical actions and documentation expectations for regulatory compliance. Step 1:…